Cited by 127Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

Early detection of pancreatic cancer using DNA-based molecular approaches

Singhi, Aatur D., Wood, Laura D.·2021·Nature Reviews Gastroenterology & Hepatology

Abstract

Due to its poor prognosis and the late stage at which it is typically diagnosed, early detection of pancreatic cancer is a pressing clinical problem. Advances in genomic analysis of human pancreatic tissue and other biospecimens such as pancreatic cyst fluid, pancreatic juice and blood have opened the possibility of DNA-based molecular approaches for early detection of pancreatic cancer. In this Review, we discuss and focus on the pathological and molecular features of precancerous lesions of the pancreas, including pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm and mucinous cystic neoplasm, which are target lesions of early detection approaches. We also discuss the most prevalent genetic alterations in these precancerous lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as tumour suppressor genes CDKN2A, TP53 and SMAD4. We highlight the latest discoveries related to genetic heterogeneity and multifocal neoplasia in precancerous lesions. In addition, we review specific approaches, challenges and clinically available assays for early detection of pancreatic cancer using DNA-based molecular techniques. Although detection and risk stratification of precancerous pancreatic neoplasms are difficult problems, progress in this field highlights the promise of molecular approaches for improving survival of patients with this disease.

Integrity signals

Registry

Crossref · 10.1038/s41575-021-00470-0

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many circulating tumor-derived analytes (proteins, autoantibodies, metabolites, DNA, non-coding RNAs, extracellular vesicles) have been assessed for PDAC early detection.

    “a multitude of circulating tumor-derived analytes (proteins, autoantibodies, metabolites, DNA, non-coding RNAs and extracellular vesicles, among others) have been assessed in the context of PDAC early detection39–41.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [40]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singhi, A. D., & Wood, L. D.
Affiliations
  • University of Pittsburgh Medical Center (US)
  • Johns Hopkins University (US)
Corresponding author
Wood, Laura D.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2021-06-07
Volume
18
Issue
7
Pages
457-468
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3166156446
Cited by
127
References
104
Citations by year
2026: 7 · 2025: 24 · 2024: 32 · 2023: 28 · 2022: 29 · 2021: 7
FWCI
2.91
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic cancer, early detection, pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, KRAS mutation, GNAS mutation, CDKN2A, TP53, SMAD4, genetic heterogeneity, liquid biopsy, pancreatic cyst fluid, blood-based biomarkers, risk stratification
MeSH terms
DNA, Neoplasm, Humans, Mutation, Pancreatic Neoplasms, Precancerous Conditions, Biomarkers, Tumor, Sequence Analysis, DNA, Genetic Heterogeneity, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review